EU approves Tivicay for HIV treatment-Viiv HealthCare
ViiV Healthcare announced that the European Commission has approved Tivicay (dolutegravir), an integrase inhibitor, for use in combination with other anti-retroviral medicinal products for the treatment of HIV infected adults and adolescents above 12 years of age.
The efficacy of Tivicay � as a �third agent� � was statistically superior to its comparator in two pivotal Phase III studies,and non-inferior in a third comparator study. In clinical trials1-, Tivicay had low rates of discontinuation due to adverse events (1-3%) in both treatment-naive and treatment-experienced patients.
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.